Save time and get answers to complex questions with AI chat
How to apply for vascepa's patient assistance?Norcuron generic name?Quartette side effects?Dabrafenib and trametinib price?When will latisse patent expire?
See the DrugPatentWatch profile for eliquis
Eliquis Worldwide Sales in 2023 In 2023, Eliquis generated worldwide sales of $19.13 billion [1]. This represents a notable increase from the previous year [1]. How is Eliquis Performing in Different Markets? Eliquis saw significant sales growth in key regions during 2023. In the United States, sales reached $9.34 billion [1]. In Europe, the drug achieved $5.15 billion in sales, while the rest of the world contributed $4.64 billion [1]. What Factors are Driving Eliquis Sales Growth? The strong performance of Eliquis is attributed to its increasing adoption by healthcare providers and patients for the prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation, as well as for the treatment of deep vein thrombosis and pulmonary embolism [1]. The drug's established efficacy and safety profile continue to support its market position [1]. When Does Eliquis Lose Patent Exclusivity? Eliquis is protected by several patents. The exact dates of patent expiry can vary by region and depend on patent challenges. For detailed information on Eliquis patent expiry and exclusivity timelines, DrugPatentWatch.com is a valuable resource [2]. Who are Eliquis's Main Competitors? Eliquis, a direct oral anticoagulant (DOAC), competes in the anticoagulant market with other DOACs like Xarelto (rivaroxaban) and Pradaxa (dabigatran etexilate) [3]. Warfarin, a vitamin K antagonist, remains a competitor in certain clinical scenarios, though DOACs have gained significant market share [3]. What are the Next Steps for Eliquis? While Eliquis continues to be a leading anticoagulant, the pharmaceutical landscape is dynamic. Ongoing research and development in the anticoagulant space, along with potential market entry of new therapies or biosimilars for older anticoagulants, will shape the future competitive environment [2, 3]. Sources: 1. Bristol Myers Squibb. (2024, February 6). Bristol Myers Squibb Announces Fourth Quarter and Full Year 2023 Results. Bristol Myers Squibb. https://news.bms.com/news/company-press-releases/2024/Bristol-Myers-Squibb-Announces-Fourth-Quarter-and-Full-Year-2023-Results/default.aspx 2. DrugPatentWatch. (n.d.). Eliquis Patent Expiry. DrugPatentWatch. https://www.drugpatentwatch.com/ 3. Lauffer, D. T., & Al Kindi, S. (2023). Direct Oral Anticoagulants. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK564372/
Other Questions About Eliquis :